Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?

被引：1
|
作者：
Ernest-Suarez, Kenneth [1 ]
Lu, Cathy [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 57卷 / 06期
关键词：
D O I：
10.1111/apt.17351
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：733 / 734
页数：2
相关论文
共 48 条
  • [1] Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply
    Buisson, Anthony
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 735 - 736
  • [2] REAL-WORLD MULTICENTER COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
    Buisson, Anthony
    Nachury, Maria
    Fumery, Mathurin
    Guilmoteau, Thomas
    Leclerc, Eloise
    Altwegg, Romain
    Serrero, Melanie
    Mathieu, Nicolas
    Treton, Xavier
    Vuitton, Lucine
    Pereira, Bruno
    Amiot, Aurelien
    Bouguen, Guillaume
    GASTROENTEROLOGY, 2022, 162 (07) : S604 - S604
  • [3] Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
    Buisson, A.
    Nachury, M.
    Fumery, M.
    Guilmoteau, T.
    Leclerc, E.
    Altwegg, R.
    Serrero, M.
    Mathieu, N.
    Treton, X.
    Vuitton, L.
    Pereira, B.
    Amiot, A.
    Bouguen, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I120 - I120
  • [4] Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent
    Buisson, Anthony
    Nachury, Maria
    Guilmoteau, Thomas
    Altwegg, Romain
    Treton, Xavier
    Fumery, Mathurin
    Serrero, Melanie
    Leclerc, Eloise
    Caillo, Ludovic
    Pereira, Bruno
    Amiot, Aurelien
    Bouguen, Guillaume
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 676 - 688
  • [5] Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis
    Adimadhyam, Sruthi
    Lewis, James D.
    Simon, Andrew L.
    Wolfe, Audrey E.
    Smith, Samantha
    Hou, Laura
    Moyneur, Erick
    Reynolds, Juliane S.
    Toh, Sengwee
    Dobes, Angela
    Parlett, Lauren
    Haynes, Kevin
    Burris, Jessica
    Dorand, Jennifer E.
    Long, Millie D.
    Kappelman, Michael D.
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (04) : 554 - 562
  • [6] Comparative effectiveness between ustekinumab and vedolizumab after anti-TNF failure in Ulcerative Colitis: Real-world experience
    Jairath, R.
    Zoughlami, A.
    Mahmoud, O.
    Pilote, N.
    Solitano, V
    Mohammad, D.
    Afif, W.
    Bitton, A.
    Wild, G.
    Lakatos, P. L.
    Narula, N.
    Jairath, V
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1186 - i1186
  • [7] TREATMENT PERSISTENCE RATES WITH TOFACITINIB IN A REAL-WORLD COHORT OF ANTI-TNF REFRACTORY ULCERATIVE COLITIS PATIENTS
    Conley, Thomas
    Colclough, James
    Liu, Eleanor
    Razanskaite, Violeta
    Jakobek, William
    Limdi, Jimmy
    Flanagan, Paul
    Subramanian, Sreedhar
    GUT, 2021, 70 : A88 - A89
  • [8] Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent
    Fumery, Mathurin
    Serrero, Melanie
    Bouguen, Guillaume
    Amiot, Aurelien
    Altwegg, Romain
    Nachury, Maria
    Vuitton, Lucine
    Treton, Xavier
    Caillo, Ludovic
    Pereira, Bruno
    Buisson, Antony
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (10) : 1615 - 1621
  • [9] Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn's Disease After Failure of Anti-TNF Agents: Real-World Evidence
    Alamer, A.
    Al Lehaibi, L.
    Alomar, M.
    Aldhuwayan, F.
    Alshouish, S.
    Al-Ali, A.
    Almudhry, Z.
    Almulhim, A.
    Althagafi, A.
    Aldosari, S.
    Alameel, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1297 - I1297
  • [10] Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
    Yarur, A.
    Mantzaris, G.
    Silverberg, M.
    Walshe, M.
    Zezos, P.
    Stein, D.
    Bassel, M.
    Lissoos, T.
    Lopez, C.
    Natsios, A.
    Radulescu, G.
    Patel, H.
    Demuth, D.
    Bressler, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S400 - S401
12345